Trials / Terminated
TerminatedNCT04023721
Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic, Hepatitis B e Antigen-negative Subjects Infected With HBV Virus and Receiving or Stopping Treatment With a NUC Inhibitor
A Phase 2, Exploratory Study Evaluating the Safety and Antiviral Efficacy of Inarigivir Soproxil in Non-cirrhotic, Hepatitis B e Antigen-negative Subjects Infected With Chronic Hepatitis B Virus and Receiving or Stopping Treatment With a Nucleoside/Nucleotide Inhibitor
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 64 (actual)
- Sponsor
- F-star Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
An open-label, Phase 2, exploratory study to examine the safety and efficacy of inarigivir in non-cirrhotic, hepatitis B e antigen (HBeAg)-negative subjects with chronic HBV infection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Inarigivir soproxil | Inarigivir soproxil 200 mg tablets |
| DRUG | Nucleoside/nucleotide (NUC) analogue inhibitors | Continuation of prestudy NUC therapy |
Timeline
- Start date
- 2019-06-18
- Primary completion
- 2020-07-16
- Completion
- 2020-07-16
- First posted
- 2019-07-17
- Last updated
- 2020-07-22
Locations
7 sites across 2 countries: Canada, United Kingdom
Source: ClinicalTrials.gov record NCT04023721. Inclusion in this directory is not an endorsement.